Serum HER2 extracellular domain as a predictive biomarker for trastuzumab deruxtecan treatment response in HER2-positive gastric cancer: a real-world study

Background: No established predictive biomarker beyond tissue HER2 status currently exists for trastuzumab deruxtecan (T-DXd) treatment response in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC). Serum HER2 extracellular domain (HER2 ECD) has shown potential i...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Yukiya Narita, Ryosuke Kumanishi, Koshi Takahashi, Toshiki Masuishi, Hiroya Taniguchi, Shigenori Kadowaki, Kazunori Honda, Masashi Ando, Tadahisa Fukui, Masahiro Tajika, Kei Muro
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	SAGE Publishing 2026-01-01
Saila:	Therapeutic Advances in Gastroenterology
Sarrera elektronikoa:	https://doi.org/10.1177/17562848251410771
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!